Background: Despite the increasing use of intravenous (IV) tenecteplase (TNKase) for acute ischemic stroke (AIS), little is known about the characteristics of patients who suffer intracerebral ...

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

Introduction: Tenecteplase (TNK) has 14-times greater specificity for fibrin and a longer half-life compared to alteplase (ALT), offering practical advantages for ease of administration and cost ...

According to NICE, Metalyse costs less than alteplase, so could save the NHS millions of pounds when used as a stroke treatment. So-called thrombolytic therapies like alteplase and tenecteplase ...

"The findings of the PUMICE randomized clinical trial indicate that thrombolysis with prourokinase did not demonstrate ...

About 795,000 Americans will have a stroke this year, but new research suggests that a common, healthy habit may reduce the risk of certain types of stroke. “We aimed to determine which oral ...

The authors suggest that the incremental costs associated with this regimen were offset by the savings afforded through the avoidance of additional stroke-related costs (Sarasin et al., ...

Stroke refers to an acute cerebrovascular disorder that is manifested by sudden loss or deterioration of brain function, resulting either from ischaemic stroke or intracranial haemorrhage. Here ...